

SUPPLEMENTARY TABLE S2. CHARACTERISTICS OF PATIENTS WITH FOLLICULAR THYROID CARCINOMA AND DISTANT METASTASIS

No	Age	Sex	Time to metastasis	Sites of metastasis	RAI avidity	Other Tx	RAS mutation ^a	Survival year and status
<i>RAS mutation positive</i>								
1	65	F	Synchronous	Lung	Refractory	None	NRAS Q61R	5.8 Alive
2	82	F	Synchronous	Lung	Avid	None	NRAS Q61R	1.3 Expired
3	45	F	Synchronous	Lung	Avid	None	NRAS Q61R	14.6 Alive
4	66	F	Synchronous	Bone	Avid	EBRT	NRAS Q61R	3.1 Alive
5	67	F	Synchronous	Lung, bone	Refractory	EBRT	NRAS Q61R	3.4 Alive
6	74	F	Synchronous	Bone	Avid	None	NRAS Q61R	7.9 Alive
7	47	M	Synchronous	Bone	Avid	None	NRAS Q61K	3.2 Alive
8	67	M	Synchronous	Lung, bone	Avid	None	NRAS Q61R	6.7 Alive
9	61	F	Metachronous (1 year)	Lung, bone	Avid	EBRT	NRAS Q61K	9.9 Expired
10	70	F	Synchronous	Multiple	Refractory	EBRT	NRAS Q61R	5.3 Alive
11	73	F	Synchronous	Multiple	Avid	EBRT, docetaxel	NRAS Q61K	5.7 Expired
12	42	F	Synchronous	Lung	Avid	None	NRAS Q61R	8.5 Alive
13	54	F	Metachronous (1.6 years)	Lung	Refractory	Lenvatinib ^b	NRAS Q61K	4.8 Alive
14	77	F	Metachronous (3.8 years)	Lung	Refractory	None	HRAS Q61R	7.5 Alive
15	69	F	Metachronous (8.3 years)	Multiple	Avid	EBRT	HRAS Q61K	12.8 Expired
16	60	M	Synchronous	Bone	Avid	EBRT	KRAS Q61R	15.6 Alive
17	69	F	Synchronous	Bone	Avid	EBRT	KRAS Q61R	2.8 Alive
<i>RAS mutation negative</i>								
18	67	F	Synchronous	Lung	Refractory	None	NA	2.9 Alive
19	67	M	Metachronous (1.1 years)	Lung, bone	Avid	None	NA	7.2 Expired
20	48	M	Metachronous (3.9 years)	Lung, bone	Avid	Sorafenib	NA	8.8 Alive
21	71	F	Synchronous	Lung, bone	Avid	Capecitabine	NA	6.6 Expired
22	53	F	Synchronous	Lung, bone	Avid	None	NA	6.8 Alive
23	55	F	Synchronous	Lung, bone	Avid	Paclitaxel	NA	3.8 Expired
24	60	F	Synchronous	Lung, bone	Avid	EBRT	NA	4.9 Alive
25	80	F	Synchronous	Multiple	Refractory	EBRT	NA	6.3 Expired
26	80	F	Synchronous	Multiple	Avid	EBRT	NA	2.8 Expired
27	62	M	Metachronous (8.0 years)	Lung	Refractory	None	NA	9.8 Alive
28	47	F	Synchronous	Multiple	Avid	None	NA	0.8 Alive

^aAmino acids: Q, glutamine; R, arginine; K, lysine.

^bShe participated in a randomized controlled phase-3 study of lenvatinib vs. placebo since September 2012. EBRT, external beam radiation therapy; F, female; F/U, follow up; M, male; NA, not applicable; No, number; RAI, radioactive iodine; Tx, treatment.